Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test an HIV prevention intervention in a Russian substance abuse treatment facility using a randomized trial study design.


Clinical Trial Description

A randomized controlled trial of an HIV prevention intervention in a narcology hospital using a stratified randomization design (by gender and substance use diagnosis) will be implemented.

We will conduct a trial among 180 inpatient subjects undergoing treatment at the LRCA. This adapted HIV prevention intervention (adapted Enhanced-RESPECT), Project RESPECT, is a 2-session, one-on-one HIV prevention counseling and testing activity with a trained health educator. By random assignment, half of the subjects will receive the Enhanced-RESPECT intervention, which will include 3 additional booster sessions. And half will receive CDC post-test counseling or standard of care depending on the results of their HIV antibody test. The post-test counseling will follow CDC counseling and testing guidelines. Subjects in the Control group who are not HIV-infected will receive the current standard of care in Russia for non-infected patients; receipt of negative test results by a clinician. HIV pre-test counseling occurs within the first 48 hours of patient arrival at LRCA. CDC post-test counseling guidelines represent a higher standard of care than currently exists within this facility for HIV-infected patients and is equivalent to the standard of care recommended for US HIV testing facilities.

All study participants will be evaluated regarding substance abuse and HIV risk behaviors at baseline and follow-up. Follow up interviews will take place at 3 time points (just before discharge from the hospital and at 3 and 6 months post-randomization). All Intervention participants will receive the basic 2-session adapted RESPECT intervention while inpatients; booster sessions for adapted Enhanced-RESPECT HIV Intervention participants will take place after discharge. Booster sessions will be offered once a month for 3 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00183118
Study type Interventional
Source Boston Medical Center
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 2004
Completion date December 2005

See also
  Status Clinical Trial Phase
Completed NCT02901041 - Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism Phase 3
Completed NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Completed NCT02705898 - Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women N/A
Completed NCT02486900 - Neurofeedback & Alcohol Dependence N/A
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02197598 - Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Phase 4
Recruiting NCT02385643 - The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients N/A
Completed NCT01828866 - Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients N/A
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT02193204 - Chronic Alcohol, Stress Inflammatory Response and Relapse Risk N/A
Completed NCT01342549 - Treatment Strategy for Alcohol Use Disorders in Veterans With TBI Phase 3
Completed NCT01165541 - A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency Phase 2
Completed NCT01176591 - HBPL Study of the Impact of the NK1 Antagonist Aprepitant Phase 2
Completed NCT01056484 - Mindfulness Meditation for Health Phase 2
Completed NCT00585780 - Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse Phase 1/Phase 2
Completed NCT00607620 - Disseminating Organizational SBI Services at Trauma Centers N/A
Completed NCT00884884 - Aripiprazole and Topiramate on Free-Choice Alcohol Use Phase 2/Phase 3
Completed NCT00463346 - Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism Phase 3
Completed NCT00226694 - Alcohol and Gender Effects on Stress Circuit Function N/A